SG10201510086VA - Drug selection for malignant cancer therapy using antibody-based arrays - Google Patents
Drug selection for malignant cancer therapy using antibody-based arraysInfo
- Publication number
- SG10201510086VA SG10201510086VA SG10201510086VA SG10201510086VA SG10201510086VA SG 10201510086V A SG10201510086V A SG 10201510086VA SG 10201510086V A SG10201510086V A SG 10201510086VA SG 10201510086V A SG10201510086V A SG 10201510086VA SG 10201510086V A SG10201510086V A SG 10201510086VA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- cancer therapy
- drug selection
- malignant cancer
- based arrays
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426948P | 2010-12-23 | 2010-12-23 | |
| US201161438904P | 2011-02-02 | 2011-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201510086VA true SG10201510086VA (en) | 2016-01-28 |
Family
ID=45464137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013046925A SG191230A1 (en) | 2010-12-23 | 2011-12-21 | Drug selection for malignant cancer therapy using antibody-based arrays |
| SG10201510086VA SG10201510086VA (en) | 2010-12-23 | 2011-12-21 | Drug selection for malignant cancer therapy using antibody-based arrays |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013046925A SG191230A1 (en) | 2010-12-23 | 2011-12-21 | Drug selection for malignant cancer therapy using antibody-based arrays |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140024548A1 (en) |
| EP (1) | EP2656077A1 (en) |
| JP (1) | JP2014503821A (en) |
| KR (1) | KR20140002711A (en) |
| CN (1) | CN103384828A (en) |
| AU (1) | AU2011348256A1 (en) |
| CA (1) | CA2822283A1 (en) |
| IL (1) | IL227009B (en) |
| MX (1) | MX2013007429A (en) |
| NZ (1) | NZ612483A (en) |
| SG (2) | SG191230A1 (en) |
| WO (1) | WO2012088337A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2990487A1 (en) | 2008-05-08 | 2016-03-02 | Asuragen, INC. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
| AU2012253422B2 (en) | 2011-05-10 | 2015-08-13 | Société des Produits Nestlé S.A. | Methods of disease activity profiling for personalized therapy management |
| WO2013086031A1 (en) * | 2011-12-05 | 2013-06-13 | Nestec S.A. | Method of therapy selection for patients with cancer |
| EP3640645A1 (en) | 2012-10-05 | 2020-04-22 | Prometheus Biosciences, Inc. | Methods for predicting and monitoring mucosal healing |
| ES2705328T3 (en) * | 2012-12-21 | 2019-03-22 | Janssen Biotech Inc | Multistage sensitive immunoassay for soluble fibroblast growth factor receptors |
| EP2954068B8 (en) | 2013-02-05 | 2018-10-31 | Pierian Holdings, Inc. | Drug selection for non-small cell lung cancer therapy |
| WO2014122600A1 (en) | 2013-02-05 | 2014-08-14 | Nestec S.A. | Methods of selecting combination therapy for colorectal cancer patients |
| EP2970126B1 (en) | 2013-03-15 | 2019-03-06 | Exelixis, Inc. | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
| CN105745335A (en) * | 2013-08-14 | 2016-07-06 | 佳根曼斯菲尔德有限公司 | Compositions and methods for multimodal analysis of cMET nucleic acids |
| WO2015110989A1 (en) | 2014-01-23 | 2015-07-30 | Nestec S.A. | Biomarker panel for assessment of mucosal healing |
| KR102338678B1 (en) * | 2014-04-03 | 2021-12-13 | 삼성전자주식회사 | Biomarker for predicting effect of an anti-c-Met antibody |
| EP2937421B1 (en) * | 2014-04-03 | 2018-10-24 | Samsung Electronics Co., Ltd | Biomarker for predicting effect of an anti-C-met antibody |
| KR20160024639A (en) | 2014-08-26 | 2016-03-07 | 삼성전자주식회사 | PDGF as a biomarker for predicting resistance or effect of c-Met targeting drugs |
| WO2016063204A1 (en) | 2014-10-20 | 2016-04-28 | Nestec S.A. | Methods for prediction of anti-tnf alpha drug levels and autoantibody formation |
| WO2016081773A2 (en) * | 2014-11-19 | 2016-05-26 | Mirna Therapeutics, Inc. | Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides |
| CN105891496A (en) * | 2014-12-09 | 2016-08-24 | 上海华盈生物医药科技有限公司 | Tyrosine kinase inhibitor targeted medication guidance antibody chip and detection method |
| WO2016196774A1 (en) * | 2015-06-03 | 2016-12-08 | Aelan Cell Technologies, Inc. | Methods and devices for the production and delivery of beneficial factors from stem cells |
| SG11201810694WA (en) * | 2016-06-03 | 2018-12-28 | Singapore Health Serv Pte Ltd | Use of biomarkers in determining susceptibility to disease treatment |
| KR20180046256A (en) * | 2016-10-27 | 2018-05-08 | 삼성전자주식회사 | Biomarker HGF for predicting effect of c-Met inhibitor |
| WO2018220588A1 (en) | 2017-05-31 | 2018-12-06 | Nestec S.A. | Methods for assessing mucosal healing in crohn's disease patients |
| TWI682176B (en) * | 2017-09-18 | 2020-01-11 | 國立臺灣大學 | Biomarker for prognosis of thyroid cancer |
| CN116597893B (en) * | 2023-06-14 | 2023-12-15 | 北京金匙医学检验实验室有限公司 | Method for predicting drug resistance gene-pathogenic microorganism attribution |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5532138A (en) | 1990-04-26 | 1996-07-02 | Behringwerke Ag | Method and kits for determining peroxidatively active catalysts |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| EP0626012B1 (en) | 1992-02-11 | 2003-07-09 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5332662A (en) | 1992-07-31 | 1994-07-26 | Syntex (U.S.A.) Inc. | Methods for determining peroxidatively active substances |
| DE69308573T2 (en) | 1992-08-17 | 1997-08-07 | Genentech Inc | SPECIFIC IMMUNOADHESINE |
| WO1995006877A1 (en) | 1993-09-03 | 1995-03-09 | Behringwerke Ag | Fluorescent oxygen channeling immunoassays |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| US6897073B2 (en) | 1998-07-14 | 2005-05-24 | Zyomyx, Inc. | Non-specific binding resistant protein arrays and methods for making the same |
| US6780582B1 (en) | 1998-07-14 | 2004-08-24 | Zyomyx, Inc. | Arrays of protein-capture agents and methods of use thereof |
| US6197599B1 (en) | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
| US7179638B2 (en) | 1999-07-30 | 2007-02-20 | Large Scale Biology Corporation | Microarrays and their manufacture by slicing |
| JP2004506201A (en) | 2000-08-03 | 2004-02-26 | マサチューセッツ・インスティチュート・オブ・テクノロジー | Microarray of functional biomolecules and uses thereof |
| AU2002303384A1 (en) | 2001-04-17 | 2002-10-28 | William J. Dower | Epitope-captured antibody display |
| US20030153013A1 (en) | 2002-11-07 | 2003-08-14 | Ruo-Pan Huang | Antibody-based protein array system |
| US20060263837A1 (en) | 2004-06-17 | 2006-11-23 | Liu George D | Immunoassay system and method for detection of antigens |
| US7771955B2 (en) | 2005-06-09 | 2010-08-10 | University Of Maryland | Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule |
| AU2007299774B2 (en) | 2006-09-21 | 2013-10-24 | Société des Produits Nestlé S.A. | Antibody-based arrays for detecting multiple signal transducers in rare circulating cells |
| PT2129396E (en) * | 2007-02-16 | 2013-11-18 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| JP2010522554A (en) | 2007-03-27 | 2010-07-08 | ロゼッタ ゲノミックス エルティーディー． | Gene expression signatures for cancer classification |
| ES2529790T3 (en) * | 2007-04-13 | 2015-02-25 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer resistant to therapeutic agents of ERBB |
| CA2693013A1 (en) | 2007-07-13 | 2009-01-22 | Prometheus Laboratories Inc. | Drug selection for lung cancer therapy using antibody-based arrays |
| DK2250498T3 (en) | 2008-02-25 | 2013-02-04 | Nestec Sa | PHARMACEUTICAL CHOICES FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS |
| CL2009000545A1 (en) * | 2008-03-06 | 2010-10-15 | Genentech Inc | Use of a c-met antagonist and a her antagonist for the treatment of cancer. |
| UY31800A (en) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | CANCER TREATMENT METHOD USING A CMET AND AXL INHIBITOR AND AN ERBB INHIBITOR |
| US8301258B2 (en) | 2008-08-14 | 2012-10-30 | The Chinese University Of Hong Kong | Methods and devices for preventing ankle sprain injuries |
| CN101837129B (en) * | 2009-03-19 | 2012-12-12 | 鼎泓国际投资（香港）有限公司 | Medicament composition containing cMet inhibitor, HDAC (Histone Deacetylases) inhibitor and EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor and application thereof |
| CN101836991B (en) * | 2009-03-19 | 2013-05-22 | 鼎泓国际投资（香港）有限公司 | Medicament composition containing sorafenib, cMet inhibitors and EGFR tyrosine kinase inhibitors and application thereof |
| EP2430443B1 (en) | 2009-05-14 | 2018-06-27 | Pierian Holdings, Inc. | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
| CA2768013C (en) * | 2009-07-15 | 2018-08-21 | Prometheus Laboratories Inc. | Drug selection for gastric cancer therapy using antibody-based arrays |
| CA2777934A1 (en) | 2009-10-20 | 2011-04-28 | Prometheus Laboratories Inc. | Proximity-mediated assays for detecting oncogenic fusion proteins |
| WO2014122600A1 (en) * | 2013-02-05 | 2014-08-14 | Nestec S.A. | Methods of selecting combination therapy for colorectal cancer patients |
-
2011
- 2011-12-21 JP JP2013546392A patent/JP2014503821A/en active Pending
- 2011-12-21 SG SG2013046925A patent/SG191230A1/en unknown
- 2011-12-21 NZ NZ61248311A patent/NZ612483A/en not_active IP Right Cessation
- 2011-12-21 AU AU2011348256A patent/AU2011348256A1/en not_active Abandoned
- 2011-12-21 MX MX2013007429A patent/MX2013007429A/en unknown
- 2011-12-21 SG SG10201510086VA patent/SG10201510086VA/en unknown
- 2011-12-21 CN CN2011800682698A patent/CN103384828A/en active Pending
- 2011-12-21 CA CA2822283A patent/CA2822283A1/en not_active Abandoned
- 2011-12-21 KR KR1020137019356A patent/KR20140002711A/en not_active Application Discontinuation
- 2011-12-21 EP EP11805738.9A patent/EP2656077A1/en not_active Withdrawn
- 2011-12-21 WO PCT/US2011/066624 patent/WO2012088337A1/en active Application Filing
-
2013
- 2013-06-17 IL IL227009A patent/IL227009B/en active IP Right Grant
- 2013-06-20 US US13/923,316 patent/US20140024548A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2822283A1 (en) | 2012-06-28 |
| JP2014503821A (en) | 2014-02-13 |
| NZ612483A (en) | 2015-03-27 |
| IL227009B (en) | 2018-03-29 |
| MX2013007429A (en) | 2014-01-31 |
| SG191230A1 (en) | 2013-07-31 |
| US20140024548A1 (en) | 2014-01-23 |
| KR20140002711A (en) | 2014-01-08 |
| CN103384828A (en) | 2013-11-06 |
| EP2656077A1 (en) | 2013-10-30 |
| AU2011348256A1 (en) | 2013-07-11 |
| WO2012088337A1 (en) | 2012-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL227009B (en) | Drug selection for malignant cancer therapy using antibody-based arrays | |
| HK1185414A1 (en) | Drug selection for breast cancer therapy using antibody-based arrays | |
| EP2454598A4 (en) | Drug selection for gastric cancer therapy using antibody-based arrays | |
| HRP20181385T1 (en) | Targeting abcb5 for cancer therapy | |
| ZA201000310B (en) | Drug selection for lung cancer therapy using antibody-based arrays | |
| IL215764A0 (en) | Adjuvant cancer therapy | |
| IL218118A0 (en) | Target genes for cancer therapy | |
| GB201016139D0 (en) | Cancer phosholipidome | |
| IL227558A0 (en) | Therapeutic agent for tumor | |
| IL222958A0 (en) | Cancer treatment | |
| EP2524702A4 (en) | Diagnostic for cancer | |
| EP2480563A4 (en) | Bladder cancer specific ligand peptides | |
| EP2522366A4 (en) | Targeting agent for tumor site | |
| IL225465A0 (en) | Picropodophyllin polymorphs b or c for use in cancer therapy | |
| EP2585115A4 (en) | Cancer therapy | |
| EP2486929A4 (en) | Therapeutic agent for tumor | |
| GB0910751D0 (en) | Prostate cancer vaccine | |
| EP2473613A4 (en) | Cancer starvation therapy | |
| GB201106630D0 (en) | Cancer therapy | |
| EP2768510A4 (en) | Camalexin as a treatment for prostate cancer | |
| GB201020513D0 (en) | Cancer therapy | |
| GB0913603D0 (en) | Cancer therapy | |
| GB0921102D0 (en) | Cancer Therapy | |
| GB201118220D0 (en) | Cancer therapy | |
| AU2010905198A0 (en) | Cancer therapy |